Mantle Irradiation Alone for Clinical Stage I-II Hodgkin's Disease: Long-Term Follow-Up and Analysis of Prognostic Factors in 261 Patients
- 1 January 1999
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (1), 230
- https://doi.org/10.1200/jco.1999.17.1.230
Abstract
PURPOSE: To evaluate mantle radiotherapy (MRT) alone as the initial therapy of patients with clinical stage (CS) I-II Hodgkin's disease (HD). PATIENTS AND METHODS: We performed a retrospective study of patients treated with MRT alone for CS I-II supradiaphragmatic HD between 1969 and 1994. Prognostic factor analysis was performed for progression-free survival (PFS) and overall survival (OS). Outcome was also assessed in favorable cohorts defined in the literature. RESULTS: There were 261 eligible patients. The median follow-up period for surviving patients was 8.4 years (range, 1.8 to 27.4 years). The 10-year OS rate was 73%. Multifactor analysis for OS showed that age was the only important prognostic factor. The 10-year PFS rate was 58%. On multifactor analysis for PFS, the most important prognostic factors were clinical stage, B symptoms, histology, number of sites, and tumor bulk. The 10-year PFS rate for lymphocyte-predominant disease was 81% for stage I and 78% for stage II. In favorable patient cohorts defined in the literature, the 10-year PFS rate ranged from 70% to 73% for the whole group and from 71% to 90% in patients with favorable stage I disease, but only from 48% to 57% in patients with favorable stage II disease. On competing-risks analysis, the cumulative 10-year incidence of first site of failure in the para-aortic/splenic region alone was 10.5%. Sixty percent of relapsed patients remain progression-free at 10 years after chemotherapy salvage. CONCLUSION: These results support the use of MRT alone in patients with favorable CS I HD and CS I-II HD with lymphocyte-predominant histology. The remainder of patients with CS I-II HD require more intensive treatment.Keywords
This publication has 37 references indexed in Scilit:
- 77 Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I–II Hodgkin's disease six-year results of the EORTC-GPMC controlled clinical trials ‘H7-VF’, ‘H7-F’ and ‘H7-U’International Journal of Radiation Oncology*Biology*Physics, 1997
- Radiation dose in Hodgkin's disease: Are we overtreating?Clinical Oncology, 1997
- Hodgkin's Disease — Time for a ChangeNew England Journal of Medicine, 1997
- Over 20 years of progress in radiation oncology: Hodgkin's diseaseSeminars in Radiation Oncology, 1997
- Breast Cancer After Treatment of Hodgkin's DiseaseJNCI Journal of the National Cancer Institute, 1993
- Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: Evidence of a more difficult rescue for patients relapsed after chemotherapyEuropean Journal Of Cancer, 1992
- Radiation therapy in clinical stage I and II Hodgkin's diseaseEuropean Journal Of Cancer, 1992
- Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.BMJ, 1992
- A multivariate analysis of prognostic factors in early stage hodgkin's diseaseInternational Journal of Radiation Oncology*Biology*Physics, 1985
- The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962–1984International Journal of Radiation Oncology*Biology*Physics, 1985